News >

Eng Highlights Important Treatment Considerations in mCRC

Kristi Rosa
Published: Thursday, Feb 21, 2019

Cathy Eng, MD

Cathy Eng, MD
In patients with newly diagnosed metastatic colorectal cancer (mCRC), it is important for oncologists to perform molecular testing early on in the process in order to create a plan for their patients, said Cathy Eng, MD, FACP, who also emphasized the significance of sidedness in this population.

“It’s very important for oncologists to recognize the importance of molecular testing early on in the treatment [of these patients] instead of just waiting for third- or fourth-line chemotherapy,” said Eng. “You have to think ahead and [figure out] what's going to be your next step if your patient is intolerant of treatment or has an allergic sensitivity reaction. You want to have a strategic plan for your patients.”

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication